Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)

NCT04541797 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT04541797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04541797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics with Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM)
Lead sponsor
The University of Hong Kong
Phase
Not applicable
Overall status
Active, not recruiting
Start date
October 1, 2020
Completion date
February 28, 2025
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

microvascular coronary artery disease, type 2 diabetes